Pfizer’s Akero Therapeutics AKRO Stock Holding History

Pfizer’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-562,626	Closed	-$15.7M	–	22
2024 Q4	$15.7M	Buy	+562,626	New	+$17M	0.6%	9

Other funds holding AKRO

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Pfizer's AKRO Position: Q1 2025 in Review

Pfizer sold out of Akero Therapeutics (AKRO) in Q1 2025, closing a stake of 562,626 shares — an estimated $15.7M sold.

Pfizer first reported a position in AKRO in Q4 2024 and held it in 1 quarter. The position peaked at $15.7M in Q4 2024. 240 funds tracked by Wall St. Rank hold AKRO as of Q1 2025.

Pfizer reported no remaining Akero Therapeutics position as of Q1 2025 after selling out during the quarter.
Pfizer sold 562,626 Akero Therapeutics shares in Q1 2025, an estimated $15.7M.
Pfizer first reported a position in Akero Therapeutics in Q4 2024 and held it in 1 quarter.
Pfizer's Akero Therapeutics position peaked at $15.7M in Q4 2024.
240 funds tracked by Wall St. Rank held Akero Therapeutics as of Q1 2025.

Based on Pfizer's 13F filing for Q1 2025, filed 13 May 2025.